Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13821341 | 0.91 | BTK (0.54) | BTKHDAC6RAF1BRAFMAPT | |
| SCHEMBL13771354 | 0.91 | BTK (0.54) | BTKHDAC6RAF1BRAFMAPT | |
| SCHEMBL2999693 | 0.89 | BTK (0.65) | BTK | |
| SCHEMBL4095817 | 0.89 | BTK (0.58) | BTKHDAC6RAF1BRAF | |
| SCHEMBL4080570 | 0.89 | BTK (0.52) | BTKHDAC6 | |
| SCHEMBL4090496 | 0.89 | BTK (0.52) | BTKHDAC6MAPTNPSR1TDP1 | |
| SCHEMBL4091723 | 0.87 | BTK (0.52) | BTKHDAC6MAPTNPSR1TDP1 | |
| SCHEMBL4091778 | 0.87 | BTK (0.51) | BTKHDAC6MAPTTP53 | |
| SCHEMBL4091659 | 0.86 | BTK (0.51) | BTKHDAC6RAF1BRAFMAPT | |
| SCHEMBL4087271 | 0.85 | BTK (0.55) | BTKHDAC6RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885HDAC6 1266/4885RAF1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.